| Trial ID: | L4345 |
| Source ID: | NCT01964963
|
| Associated Drug: |
Alogliptin
|
| Title: |
Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01964963/results
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Alogliptin
|
| Outcome Measures: |
Primary: Percentage of Participants Who Had One or More Adverse Events, Up to Month 36|Change From Baseline in Glycosylated Hemoglobin (HbA1c), The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at final assessment point (up to Month 36) relative to baseline., Baseline, and final assessment point (up to Month 36) | Secondary: Change From Baseline in Fasting Blood Glucose, The change in the value of fasting blood glucose level collected at final assessment point (up to Month 36) relative to baseline., Baseline, and final assessment point (up to Month 36)
|
| Sponsor/Collaborators: |
Sponsor: Takeda
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
19192
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2011-08-03
|
| Completion Date: |
2017-07-31
|
| Results First Posted: |
2019-05-09
|
| Last Update Posted: |
2019-11-21
|
| Locations: |
Tokyo, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01964963
|
